VYVGART HYTRULO FDA approval date

The FDA approved VYVGART HYTRULO on 20 Jun 2023.

FDA approval date
20 Jun 2023

Drug identity has not yet been verified against registry records

Also recorded as EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-06-20DayVYVGART HYTRULOFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761304", "applicant_as_listed_by_fda": "ARGENX BV", "brand_names": ["VYVGART HYTRULO"], "active_ingredients": ["EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230620", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026